<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689364</url>
  </required_header>
  <id_info>
    <org_study_id>WJB730603</org_study_id>
    <nct_id>NCT00689364</nct_id>
  </id_info>
  <brief_title>Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer</brief_title>
  <official_title>Retrospective-Prospective Cohort Study Effectiveness of Comprehensive Therapy of TCM to Relieving the Risk of Recurrence and Metastasis for Stage II &amp; III Colorectal Cancer Based on Conventional Western Medicine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Centre of Complementary and Alternative Medicine, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Science and Technology of the People´s Republic of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comprehensive therapy of traditional Chinese medicine (CTTCM) could relieve risk of&#xD;
      recurrence and metastasis for stage II &amp; III colorectal cancer, the investigators take this&#xD;
      clinical trial with retrospective-prospective cohort study based on previous studies by&#xD;
      international multi-center way.&#xD;
&#xD;
      If the study shows a positive result, a pragmatic randomized controlled study with&#xD;
      prospective, multi-centre and large-sample design will be given continuously. The aim is to&#xD;
      establish recommended programs suggested by CTTCM strategies under conventional Western&#xD;
      medicine therapy (CWMT) for stage II &amp; III colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTTCM: taking TCM decoction based on syndrome differentiation daily and each dosage is&#xD;
      decocted two times for intervention one year with a Chinese patent medicine at least.&#xD;
&#xD;
      CWMT: with or without chemotherapy/or radiotherapy after the radical operation (R0)&#xD;
      (according to the latest NCCN clinical guideline).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The recurrence and metastasis rates for 1、2、3、4 and 5-year.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival index: the survival rate for1、2、3、4 and 5-year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CTTCT+CWMT</arm_group_label>
    <description>CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.&#xD;
CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CWMT cohort</arm_group_label>
    <description>CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CTTCT plus CWMT cohort in China:160 CWMT cohort in China:160 CWMT cohort in Norway:300&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who is diagnosed colorectal cancer by patho&amp; cytologic diagnosis since&#xD;
             accepting radical operation within half a year.&#xD;
&#xD;
          -  Stage II or III colorectal cancer.&#xD;
&#xD;
          -  18-75 yr.&#xD;
&#xD;
          -  Being able to participate and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman, Psychotic.&#xD;
&#xD;
          -  Patient who put together with other cancer.&#xD;
&#xD;
          -  Existed serious complaint and functional disturbance (impairment) with non-tumorous in&#xD;
             arch-organ.&#xD;
&#xD;
          -  Reactiveness cerebrovascular disease (CVD) .&#xD;
&#xD;
          -  Uncontrolled infection and metabolic disease.&#xD;
&#xD;
          -  One item of tumor marks is progressed, and it still is progressed when patient&#xD;
             recheck.&#xD;
&#xD;
          -  Tumor that it is neo-occurred in each organ or pelvic cavity or abdominal cavity&#xD;
             without definite patho-quality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Yufei, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Xi-Yuan Hospital, China Academy of Chinese Medical Sciences, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xi-Yuan Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100091</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xi-Yuan Hospital, China Academy of Chinese Medical Sciences</name_title>
    <organization>Department of Oncology, Xi-Yuan Hospital</organization>
  </responsible_party>
  <keyword>Cohort Study</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Risk of recurrence and metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

